posted on 2025-03-20, 07:13authored byJulia Eklund, Ulf Bremberg, Jessica Larsson, Edvard Torkelsson, Johan Wennerberg, Symantha Zandelin, Luke R. Odell
As interest in using psilocybin therapy for treating
mental health
disorders intensifies, the need for efficient production methods becomes
increasingly important. Current medical-grade psilocybin production
is inefficient and relies on a complicated multistep synthesis. This
study has explored and evaluated psilocin ester prodrugs and psilocin
salts as potential alternatives to psilocybin, focusing on their ease
of synthesis, chemical stability, and metabolic profiles. A diverse
library of 15 psilocin ester prodrugs and six psilocin salts was synthesized
and evaluated. The study successfully identified several psilocin
ester prodrugs and psilocin salts that exhibited desirable characteristics,
including storage and handling stability, rapid metabolic conversion
to psilocin, and easy synthesis, with potential advantages over psilocybin.
This research introduces viable options through psilocin ester compounds
and psilocin salts, offering promising avenues for future development.